Commission acts on CHMP Esmya advice
Executive Summary
The European Commission has “opened the way” for Gedeon Richter to relaunch in European markets the Esmya (ulipristal acetate) women’s healthcare brand, after adopting an opinion from the CHMP recommending measures to minimise the risk of rare but serious liver injury.
You may also be interested in...
EMA Safety Panel Recommends Withdrawing Esmya Authorizations
Marketing authorizations for Gedeon Richter’s Esmya and generic versions are certain to be revoked, after a review by the European Medicines Agency’s safety committee concluded that the uterine fibroids drug “can cause liver injury, including the need for liver transplantation.”
EMA Safety Commission Recommends Withdrawal Of Esmya Authorizations
Marketing authorizations for Gedeon Richter’s Esmya and generic versions are certain to be revoked, after a review by the EMA’s safety committee concluded that the uterine fibroids drug “can cause liver injury, including the need for liver transplantation.”
Slovenia Is Our Commitment; Evotec Is A Gamechanger: Sandoz’s Stenico
On the sidelines of Medicines for Europe’s 19th biosimilar conference in Amsterdam, Sandoz global biosimilars chief Peter Stenico spoke to Generics Bulletin about the firm’s preparations and strategy ahead of its proposed spinoff from Novartis later this year.